The studies highlighted that all outlets face challenges in delivering their services, but that CHWs [community health workers] scored highly in almost all parameters. CHWs have proved to be effective agents in providing correct diagnosis and treatment of malaria and other common fevers, even in remote areas. Their role should be recognized and expanded.
Over several generations, scientists expect Key West’s Aedes aegypti to dwindle along with the number of dengue infections.
“The science of it, I think, looks fine. It’s straight from setting up experiments and collecting data,” Michael Doyle, the head of the Florida Keys Mosquito Control District, said, NewsVine.com reports.
The plan uses no pesticides and can be conducted on a large scale for a relatively low cost. Because the mosquitoes carrying the genetic defect die off, the modified mosquitoes will disappear without permanently altering the species.
What do Jesuit priests, gin and tonics, and ancient Chinese scrolls have in common? They all show up in our animated history of malaria.
” If we dont scale up vector control activities in 2013 we can expect major resurgences of malaria,” said Richard Cibulskis, lead author of the WHOs W o rld Malaria Report, which was published on Monday.”Vector contol” means stopping transmission of the disease with tools such as treated mosquito nets. The report found that deliveries of such nets to endemic countries in sub-Saharan Africa dropped from 145 million in 2010 to an estimated 66 million in 2012.
This new method, called Rolling Circule-Enhanced Enzyme Activity Detection, or REEAD, is more time- and cost- effective, and easy to perform. It is also able to diagnose infections caused by all five malaria-carrying plasmodium parasites, not just the most common two (Plasmodium falciparum and Plasmodium vivax). Further, according to the Aarhus University press release, the REEAD-based method can detect whether the infecting plasmodium is drug resistant.
There is currently a $3.6 billion funding gap on malaria in Africa, according to the Roll Back Malaria Partnership, whose board concluded its 23rd meeting in Dakar, Senegal, on Dec. 7. As in other global health threats like AIDS, this could reverse gains in the fight against malaria in the continent.
Particular attention is needed in eight African countries: Nigeria, the Central African Republic, Ivory Coast, the Democratic Republic of the Congo, Ethiopia, Mauritania, Niger and Sierra Leone. These eight countries need $2.4 billion to curb malaria incidences over the next two years, with Nigeria alone requiring nearly half that amount. Nigeria has one of the highest malaria mortality rates in the world; the disease accounts for 30 percent of childhood deaths in the country.
Dr Tim Wells, MMV’s Chief Scientific Officer, said: “This is a great achievement and an excellent example of the quality of research that can be fostered in Africa. We look forward to seeing more exciting compounds emerge from Kelly’s team and are proud to be collaborating with H3-D; not only is it conducting excellent science today, but it is also providing world-class training for the next generation of African scientists.”
What is so unique and exciting about MMV390048
It is very potent: it displayed a complete cure of animals infected with malaria parasites in a single dose given orally, and thus has the potential to cure millions of people.
It is active against a wide panel of resistant strains of the malaria parasite.
Developing the drug has made possible the training of more than 10 local scientists and cemented a strong relationship with an international partner.
The clinical candidate is in line to enter clinical trials in late 2013.
View a video of Prof Kelly Chibale speaking about H3-D.